BCG
REGN icon

BayBridge Capital Group’s Regeneron Pharmaceuticals REGN Stock Holding History

BayBridge Capital Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$504K Buy
808
+387
+92% +$263K 0.26% 71
2026
Q1 		$325K Hold
421
– – 0.2% 75
2025
Q4 		$325K Buy
421
+5
+1% +$3.4K 0.2% 75
2025
Q3 		$234K Buy
+416
New +$235K 0.15% 89

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

BayBridge Capital Group's REGN Position: Q2 2026 in Review

BayBridge Capital Group increased its Regeneron Pharmaceuticals (REGN) stake by 92% in Q2 2026, buying an estimated $263K and bringing the position to 808 shares worth $504K. The position accounts for 0.26% of the portfolio, ranked #71.

BayBridge Capital Group first reported a position in REGN in Q3 2025 and has held it in 4 quarters since. 240 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • BayBridge Capital Group held 808 shares of Regeneron Pharmaceuticals worth $504K as of Q2 2026.
  • BayBridge Capital Group bought 387 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $263K.
  • Regeneron Pharmaceuticals made up 0.26% of BayBridge Capital Group's portfolio in Q2 2026, its #71 holding.
  • BayBridge Capital Group first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 240 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on BayBridge Capital Group's 13F filing for Q2 2026, filed 14 Jul 2026.